Close
CDMO Safety Testing 2026
Novotech

Zuellig pharma collaborates with Taiko on Cleverin in Taiwan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Bristol Myers Squibb Integrates AI to Advance Manufacturing Quality Systems

Bristol Myers Squibb has entered into a strategic agreement...

eschbach Unveils Seqonis Intelligent Operations Platform

eschbach has renamed its flagship enterprise software platform, Shiftconnector,...

Cell and Gene Therapy Manufacturing Entering GMP Era

The rapid and profound maturation of the global biopharmaceutical sector is being clearly marked by cell and gene therapy manufacturing entering GMP era. This critical transition involves the large-scale implementation of rigorous and uncompromising Good Manufacturing Practice standards to ensure that these complex, "living" treatments are produced with a level of consistent quality and safety that meets international requirements. By adopting highly automated systems, closed-loop processing, and robust, data-driven regulatory frameworks, the industry is successfully overcoming the historical hurdles of scalability and biological variability, paving the way for these advanced therapies to reach much broader patient populations across the globe.
- Advertisement -

Building on many years of partnership, Zuellig Pharma Taiwan and Taiko Pharmaceutical Limited have kicked off a new collaboration that will see Zuellig Pharma distribute and promote Cleverin in Taiwan. 

 

Cleverin® is a leading Japanese environmental decontamination technology, and has been listed by the US Centers for Disease Control and Prevention and Occupational Safety and Health Administration as an effective disinfectant for healthcare organization and household use. The brand sells approximately 10 million bottles in Japan every year. 

Zuellig Pharma Taiwan Chief Executive John Chou said: “Cleverin® is an innovative environmental decontaminant technology to prevent infectants spreading at home. We are proud to work with Taiko Pharmaceutical to help them make this technology available in the Taiwan market.” As part of the promotional strategy, Zuellig Pharma Taiwan organized for Taiko Pharmaceutical President Dr. Takashi Shibata to give a presentation at the Greater Taipei Area Hospital and the Densely Populated Organization Infection Control Seminar. 

“Dr. Shibata was invited to speak as an expert in chlorine dioxide gas technology and the experience the company has had in Japan with this technology,” Mr. Chou said. “The events were attended by Minister of Health and Welfare Dr. Lin Tzou-yien, and more than 800 healthcare professionals. It was therefore a great opportunity for us to raise awareness of Taiko Pharmaceutical and its expertise in this category among Taiwan’s medical community.”

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Bristol Myers Squibb Integrates AI to Advance Manufacturing Quality Systems

Bristol Myers Squibb has entered into a strategic agreement...

eschbach Unveils Seqonis Intelligent Operations Platform

eschbach has renamed its flagship enterprise software platform, Shiftconnector,...

Cell and Gene Therapy Manufacturing Entering GMP Era

The rapid and profound maturation of the global biopharmaceutical sector is being clearly marked by cell and gene therapy manufacturing entering GMP era. This critical transition involves the large-scale implementation of rigorous and uncompromising Good Manufacturing Practice standards to ensure that these complex, "living" treatments are produced with a level of consistent quality and safety that meets international requirements. By adopting highly automated systems, closed-loop processing, and robust, data-driven regulatory frameworks, the industry is successfully overcoming the historical hurdles of scalability and biological variability, paving the way for these advanced therapies to reach much broader patient populations across the globe.

How to Source the Best Color Spectrophotometers and Colorimeters for Pharma QC

Color consistency is critical in pharmaceutical quality control (QC)....

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »